BioSpace News Archive

Cellectis, a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, will present first data exploring novel TALEN® editing processes in hematopoietic stem and progenitor cells at the American Society of Gene and Cell Therapy being held on May 7-11, 2024.

Theriva™ Biologics announced the presentation of preclinical data demonstrating enhanced anti-tumor effects in human pancreatic cancer xenograft-bearing mice treated with lead product candidate VCN-01 and liposomal irinotecan.

CRISPR Therapeutics (Nasdaq: CRSP) today announced an oral presentation highlighting the Company’s lipid nanoparticle (LNP) approach for ocular editing will be presented at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, taking place May 7 – 11, 2024, in Baltimore, MD and virtually.

Excision BioTherapeutics, Inc., a clinical-stage biotechnology company developing CRISPR-based therapies to cure serious latent viral infectious diseases, announced that it will present positive data from its program for Hepatitis B virus at the American Society of Gene & Cell Therapy 2024 Annual Meeting taking place May 7-11, 2024 in Baltimore, Maryland.

Tessera Therapeutics, a biotechnology company pioneering a new approach to genome engineering through the development of its Gene Writing™ and delivery platforms, today announced six presentations of new preclinical data at the upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting taking place in Baltimore, Maryland, May 7 – 11, 2024.

Excision BioTherapeutics, Inc. (“Excision”, the “Company”) today announced that it will present positive data from its herpes simplex virus-1 keratitis program, EBT-104, as well as an overview of a next-generation AAV delivery vector, at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting taking place May 7-11, 2024 in Baltimore, Maryland.

Alltrna today announced a poster presentation at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting taking place May 7-11 in Baltimore and a talk and two poster presentations at TIDES USA 2024 taking place May 14-17 digitally and in-person in Boston.

Replicate Bioscience, a clinical-stage company pioneering novel self-replicating RNA (srRNA) technology for use in infectious disease, oncology, autoimmune disease, and more, today announced acceptance of two oral presentations at the upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, May 7-11 in Baltimore, Maryland.

Affinia Therapeutics announced that new preclinical data on its novel AAV capsids for genetic cardiomyopathies and diseases of the central nervous system such as amyotrophic lateral sclerosis, as well as the Company’s high-yield manufacturing process, will be presented in several oral and poster sessions at the American Society of Gene and Cell Therapy 2024 Annual Meeting, being held May 7-11, 2024 in Baltimore, MD and virtually.

CNS Pharmaceuticals, Inc. today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will present at the Virtual Investor Lunch Break: The CNSP Opportunity event on Tuesday, April 23, 2024 at 12:00 PM ET.